- Conditions
- Advanced Solid Tumor, Gynecologic Cancer
- Interventions
- Lucitanib, Nivolumab
- Drug
- Lead sponsor
- Clovis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2401–2424
of 7,396
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Nivolumab, HuMax-IL8
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
- Interventions
- IPH4102
- Biological
- Lead sponsor
- Innate Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 12 more
- Conditions
- Postoperative Pain
- Interventions
- HTX-011B, Placebo, HTX-011A, HTX-002, Bupivicaine HCl
- Drug
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 277 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Pasadena, California • Pasadena, Maryland + 3 more
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Interventions
- relugolix + ARPI., Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI, relugolix or androgen deprivation therapy (ADT) + ARPI
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Diabetes, Chronic Disease, Type 2 Diabetes, Healthy Lifestyle, Nutrition, Healthy, Sedentary Behavior, Family, Family Research, Family and Household
- Interventions
- Families Implementing Good Health Traditions for Life
- Behavioral
- Lead sponsor
- Morehouse School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Albany, Georgia
- Conditions
- Advanced Esophageal Cancers, Primary Small Cell Lung Cancers, Non-Small-Cell Lung Carcinoma, Pleural Mesotheliomas, Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura
- Interventions
- Decitabine, Depsipeptide, Celecoxib
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Solid Tumors Harboring NTRK Fusion
- Interventions
- Selitrectinib (BAY2731954)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 17
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 13 more
- Conditions
- Transplant, Heart, Magnetic Resonance Imaging
- Interventions
- MRI Sequencing, MRI Testing (pediatric), MRI Testing
- Diagnostic Test
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- Not listed
- Enrollment
- 247 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2030
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Healthy
- Interventions
- MBL-HCV1
- Biological
- Lead sponsor
- MassBiologics
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Brain Tumor
- Interventions
- Panitumumab-IRDye800, Pinpoint-IR9000 endoscopic/handheld device, Explorer Air camera, PDE-NEO-II
- Drug · Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 6 Months to 25 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Mild to Moderate COVID-19
- Interventions
- MBS-COV, Placebo
- Drug
- Lead sponsor
- Oneness Biotech Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Relapsed Refractory Multiple Myeloma (RRMM)
- Interventions
- Talquetamab, Mezigdomide, Dexamethasone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Solid Tumor
- Interventions
- RP-3500 (camonsertib), Talazoparib, Gemcitabine Injection
- Drug
- Lead sponsor
- Repare Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Boston, Massachusetts • New York, New York + 4 more
- Conditions
- Healthy, Liver Diseases, Obesity
- Interventions
- BI 456906
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Chandler, Arizona • Fort Myers, Florida • Sarasota, Florida + 1 more
- Conditions
- Asthma
- Interventions
- Dupilumab SAR231893 (REGN668)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 35
- States / cities
- Gilbert, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more
- Conditions
- Hypercholesterolemia
- Interventions
- ALIROCUMAB SAR236553 (REGN727)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease
- Interventions
- Lumbar puncture, Blood draw, Magnetic Resonance Imaging (MRI)
- Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- HIV Infection
- Interventions
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Nevirapine (NVP), Lopinavir/Ritonavir (LPV/r), Raltegravir (RAL), VRC01, Dolutegravir (DTG), VRC07-523LS
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 48 Hours
- Enrollment
- 1,120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2031
- U.S. locations
- 21
- States / cities
- La Jolla, California • Los Angeles, California • Aurora, Colorado + 13 more
- Conditions
- Alzheimer's Disease
- Interventions
- MABT5102A, placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 18 more
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- Etelcalcetide, Placebo
- Drug
- Lead sponsor
- KAI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 13
- States / cities
- Azusa, California • Costa Mesa, California • Lynwood, California + 9 more
- Conditions
- Relapsed/Refractory Large B-cell Lymphoma
- Interventions
- Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel, Utomilumab
- Drug · Biological
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Santa Monica, California • Tampa, Florida + 2 more
- Conditions
- Early-Stage Non-Small Cell Lung Cancer
- Interventions
- Pumitamig, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 9
- States / cities
- Long Beach, California • Los Angeles, California • Tampa, Florida + 6 more
- Conditions
- Glioma
- Interventions
- Lenvatinib, Bevacizumab
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Boston, Massachusetts • Durham, North Carolina